Company intelligence / Profile preview
ARTham Therapeutics, Inc.
Tokyo/Bunkyo-ku, Tokyo Prefecture, Japanarthamther.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
ARTham Therapeutics has advanced its lead program ART‑001, a PI3Kα inhibitor for vascular malformations, into Phase 3 clinical trials. Another program targeting PDE4 for NASH has reached Phase 1. The company’s pipeline also includes an underactive bladder therapy in preclinical or pending status. The company was acquired by Kaken Pharmaceutical in November 2021 and operates with a virtual R&D model focused on disease-modifying drugs for unmet medical needs.
- Therapeutic areas
- GastroenterologyCardiovascularDermatologyNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Takeda PharmaceuticalOita Venture CapitalKaken Pharmaceutical
Beyond the preview
Go deeper on ARTham Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARTham Therapeutics, Inc..